18F-PSMA-1007 POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN THE DIAGNOSIS OF RECURRENT PROSTATE CANCER: CLINICAL OBSERVATION

Cover Page

Cite item

Full Text

Abstract

Objective: demonstration of possibilities of 18F-prostate specific membrane antigen-1007 (18F-PSMA-1007) positron emission tomography/computed tomography (PET/CT) for diagnostic prostate cancer recurrence.

The article presents clinical observation of the patient with prostate cancer biochemical recurrence after the multiple treatment. 18F-PSMA-1007 PET/CT demonstrates high sensitivity in prostate cancer recurrence diagnostic, in particular with low prostatic specific antigen level.

About the authors

M. B. Dolgushin

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0003-3930-5998

23 Kashirskoe Shosse, Moscow 115478.

Russian Federation

N. A. Meshcheryakova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Author for correspondence.
Email: mdnadya@gmail.com
ORCID iD: 0000-0003-0770-3406

23 Kashirskoe Shosse, Moscow 115478.

Russian Federation

A. A. Odzharova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0003-3576-6156

23 Kashirskoe Shosse, Moscow 115478.

Russian Federation

V. B. Matveev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0001-7748-9527

23 Kashirskoe Shosse, Moscow 115478.

Russian Federation

D. I. Nevzorov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0003-2969-0191

23 Kashirskoe Shosse, Moscow 115478.

Russian Federation

O. E. Platonova

Medicina

ORCID iD: 0000-0003-0093-7285
10 2nd Tverskoy-Yamskoy Pereulok, Moscow 125047. Russian Federation

P. V. Kochergin

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-3899-3058

23 Kashirskoe Shosse, Moscow 115478.

Russian Federation

References

  1. Rajasekaran A.K., Anilkumar G., Christiansen J.J. Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol 2005;288(5):C975–81. doi: 10.1152/ajpcell.00506.2004. PMID: 15840561.
  2. Wright G.L. Jr, Haley C., Beckett M.L., Schellhammer P.F. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995;1(1):18–28. PMID: 21224086.
  3. Liu H., Rajasekaran A.K., Moy P. et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998;58(18):4055–60. PMID: 9751609.
  4. Giesel F.L., Hadaschik B., Cardinale J. et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 2017;44(4):678–88. doi: 10.1007/s00259-016-3573-4. PMID: 27889802.
  5. Cho S.Y., Gage K.L., Mease R.C. et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 2012;53(12):1883–91. doi: 10.2967/jnumed.112.104661. PMID: 23203246.
  6. Szabo Z., Mena E., Rowe S.P. et al. Initial evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol 2015;17(4):565–74. doi: 10.1007/s11307-015-0850-8. PMID: 25896814.
  7. Kratochwil C., Giesel F.L., Stefanova M. et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. J Nucl Med 2016;57(8):1170–6. doi: 10.2967/jnumed.115.171397.
  8. Ahmadzadehfar H., Eppard E., Kürpig S. et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget 2016;7(11):12477–88. doi: 10.18632/oncotarget.7245. PMID: 26871285.
  9. Kratochwil C, Bruchertseifer F., Giesel F.L. et al. 225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2016.
  10. Cardinale J., Schäfer M., Benesová M. et al. Preclinical evaluation of [18F] PSMA1007: a new PSMA-ligand for prostate cancer imaging. J Nucl Med 2016.
  11. Giesel F.L., Hadaschik B., Cardinale J. et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer. Eur J Nucl Med Mol Imaging 2017.
  12. Zaman M.U., Fatima N., Zaman A. et al. Diagnostic challenges in prostate cancer and 68Ga-PSMA PET imaging: a game changer? Asian Pacific J Cancer Prev 2017;18(10):2625–8. doi: 10.22034/APJCP.2017.18.10.2625. PMID: 29072055.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.